Daniel R Malan

Efficacy and Safety of Atazanavir, With or Without Ritonavir, as Part of Once-Daily Highly Active Antiretroviral Therapy Regimens in Antiretroviral-Naive Patients

Daniel R Malan, Edrich Krantz, Neal David et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2008 · 149 citations

Long‐term safety and efficacy of the anti‐tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results

Johnny Mahlangu, José Luis Lamas, Juan Cristóbal Morales et al. · British Journal of Haematology · 2022 · 58 citations · Full text

A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia

Johnny Mahlangu, José Luis Lamas, Juan Cristóbal Morales et al. · British Journal of Haematology · 2022 · 41 citations · Full text

Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma

Philip R. Clingan, Rahul Ladwa, Daniel Brungs et al. · Journal for ImmunoTherapy of Cancer · 2023 · 35 citations · Full text

Immunology, Immunoediting, Pathology +16

96-Week Efficacy and Safety of Atazanavir, With and Without Ritonavir, in a HAART Regimen in Treatment-Naive Patients

Daniel R Malan, Edrich Krantz, Neal David et al. · Journal of the International Association of Physicians in AIDS Care · 2010 · 20 citations

Atv 300, Health-related Quality, Medicine +14